Skip to main content
SpringerLink
Log in

Treatment of High-Grade Gliomas in Adults

  • Chapter
  • First Online:
Therapeutic Ribonucleic Acids in Brain Tumors

  • 400 Accesses

Abstract

Surgery, radiation therapy, and chemotherapy with temozolomide are the mainstays of treatment for patients with high-grade gliomas. The addition of temozolomide leads to a significant improvement in 2-year survival compared to radiation alone, although 2-year survival remains less than 30%. Responsiveness to temozolomide depends on the activity of O6-methylguanine-DNA methyltransferase in tumor cells. Increasing evidence suggests that certain molecular pathways are selectively upregulated in tumor cells. Some of these pathways have been shown to be instrumental in proliferation, migration, invasion, angiogenesis, and survival in preclinical models and therefore represent attractive therapeutic targets. This chapter will summarize the current standard of care of the different treatment modalities and some of the novel therapies undergoing evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abrey LE (2008) Bevacizumab in recurrent malignant glioma. Curr Neurol Neurosci Rep 8:233–234

    PubMed  Google Scholar 

  • Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707

    CAS  PubMed  Google Scholar 

  • Ali SA, McHayleh WM, Ahmad A et al (2008) Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 109:268–272

    CAS  PubMed  Google Scholar 

  • Ammirati M, Galicich JH, Arbit E et al (1987a) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614

    CAS  PubMed  Google Scholar 

  • Ammirati M, Vick N, Liao YL et al (1987b) Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21:201–206

    CAS  PubMed  Google Scholar 

  • Asthagiri AR, Pouratian N, Sherman J et al (2007) Advances in brain tumor surgery. Neurol Clin 25:975–1003, viii–ix

    PubMed  Google Scholar 

  • Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848

    CAS  PubMed  Google Scholar 

  • Batchelor T, Sorensen A, di Tomaso E et al (2007a) AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    CAS  PubMed  Google Scholar 

  • Batchelor TT, Sorensen AG, di Tomaso E et al (2007b) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    CAS  PubMed  Google Scholar 

  • Berman JI, Berger MS, Chung SW et al (2007) Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging. J Neurosurg 107:488–494

    PubMed  Google Scholar 

  • Bigner DD, Brown MT, Friedman AH et al (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16:2202–2212

    CAS  PubMed  Google Scholar 

  • Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266

    CAS  PubMed  Google Scholar 

  • Brandes AA, Ermani M, Basso U et al (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12:255–257

    CAS  PubMed  Google Scholar 

  • Brandes AA, Nicolardi L, Tosoni A et al (2006a) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncology 8:253–260

    CAS  PubMed  Google Scholar 

  • Brandes AA, Tosoni A, Cavallo G et al (2006b) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746–4753

    CAS  PubMed  Google Scholar 

  • Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197

    PubMed  Google Scholar 

  • Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461

    PubMed  Google Scholar 

  • Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012

    CAS  PubMed  Google Scholar 

  • Brem SS, DeAngelis LM, Maor MH et al (2005) Central Nervous System Cancers. Clinical Practice Guidelines in Oncology Version 1. National Comprehensive Cancer Network

    Google Scholar 

  • Broniscer A, Gururangan S, MacDonald TJ et al (2007) Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718

    CAS  PubMed  Google Scholar 

  • Cairncross G, Macdonald D, Ludwin S et al (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021

    CAS  PubMed  Google Scholar 

  • Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    CAS  PubMed  Google Scholar 

  • Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    CAS  PubMed  Google Scholar 

  • Cardinale R, Won M, Choucair A et al (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422–1428

    PubMed  Google Scholar 

  • Chamberlain MC (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 67:2089

    PubMed  Google Scholar 

  • Chamberlain MC (2008) Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:1012–1013

    PubMed  Google Scholar 

  • Chan TA, Weingart JD, Parisi M et al (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133–1139

    PubMed  Google Scholar 

  • Chang CH, Horton J, Schoenfeld D et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52:997–1007

    CAS  PubMed  Google Scholar 

  • Chang JE, Khuntia D, Robins HI et al (2007) Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 5:894–902; 907–815

    PubMed  Google Scholar 

  • Chang S, Wen P, Cloughesy T et al (2005a) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361

    CAS  PubMed  Google Scholar 

  • Chang SM, Wen P, Cloughesy T et al (2005b) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361

    CAS  PubMed  Google Scholar 

  • Chi A, Wen P (2007) Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 11:473–496

    CAS  PubMed  Google Scholar 

  • Cloughesy T, Wen P, Robins H et al (2006a) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651–3656

    CAS  PubMed  Google Scholar 

  • Cloughesy TF, Wen PY, Robins HI et al (2006b) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651–3656

    CAS  PubMed  Google Scholar 

  • Cloughesy T, Prados M, Wen P et al (2007) Phase II, Randomized, Non-Comparative Clinical Trial of Bevacizumab Alone or in Combination with CPT-11 Prolongs 6-month PFS in Recurrent, Treatment-Refractory Glioblastoma. Society for Neuro-Oncology 12th Annual Meeting

    Google Scholar 

  • Cloughesy TF, Prados MD, Mikkelsen T et al (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010b

    Google Scholar 

  • Coffey RJ, Lunsford LD, Taylor FH (1988) Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22:465–473

    CAS  PubMed  Google Scholar 

  • Coughlin C, Scott C, Langer C et al (2000) Phase II, two-arm RTOG trial (94–11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48:1351–1358

    CAS  PubMed  Google Scholar 

  • Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

    PubMed  Google Scholar 

  • Del Rowe J, Scott C, Werner-Wasik M et al (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18:1254–1259

    CAS  PubMed  Google Scholar 

  • Desjardins A, Quinn JA, Vredenburgh JJ et al (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83:53–60

    CAS  PubMed  Google Scholar 

  • Devaux BC, O'Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767–775

    CAS  PubMed  Google Scholar 

  • Dinapoli RP, Brown LD, Arusell RM et al (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11:1316–1321

    CAS  PubMed  Google Scholar 

  • Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033–4042

    CAS  PubMed  Google Scholar 

  • Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597

    CAS  PubMed  Google Scholar 

  • Fischer I, Cunliffe CH, Bollo RJ et al (2008) High-grade glioma before and after treatment with radiation and Avastin: Initial observations. Neuro-Oncology 10(5):700–708

    PubMed  Google Scholar 

  • Fitzek MM, Thornton AF, Rabinov JD et al (1999) Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 91:251–260

    CAS  PubMed  Google Scholar 

  • Ford JM, Seiferheld W, Alger JR et al (2007) Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69:831–838

    CAS  PubMed  Google Scholar 

  • Fulci G, Chiocca EA (2007) The status of gene therapy for brain tumors. Expert Opin Biol Ther 7:197–208

    CAS  PubMed  Google Scholar 

  • Furnari FB, Fenton T, Bachoo RM et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710

    CAS  PubMed  Google Scholar 

  • Galanis E, Buckner J, Maurer M et al (2005a) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304

    CAS  PubMed  Google Scholar 

  • Galanis E, Buckner JC, Maurer MJ et al (2005b) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304

    CAS  PubMed  Google Scholar 

  • Glantz MJ, Burger PC, Herndon JE et al (1991) Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 41:1741–1744

    CAS  PubMed  Google Scholar 

  • Goldschmidt N, Linetsky E, Shalom E et al T (2003) High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98:1239–1242

    PubMed  Google Scholar 

  • Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635–644

    CAS  PubMed  Google Scholar 

  • Grunert P, Ungersbock K, Bohl J et al (1994) Results of 200 intracranial stereotactic biopsies. Neurosurg Rev 17:59–66

    CAS  PubMed  Google Scholar 

  • Guerin C, Olivi A, Weingart JD et al (2004) Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 22:27–37

    CAS  PubMed  Google Scholar 

  • Guyotat J, Signorelli F, Frappaz D et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899–904

    CAS  PubMed  Google Scholar 

  • Haas-Kogan DA, Prados MD, Lamborn KR et al (2005a) Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4:1369–1372

    CAS  PubMed  Google Scholar 

  • Haas-Kogan DA, Prados MD, Tihan T et al (2005b) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887

    CAS  PubMed  Google Scholar 

  • Haberland N, Ebmeier K, Hliscs R et al (2000) Neuronavigation in surgery of intracranial and spinal tumors. J Cancer Res Clin Oncol 126:529–541

    Google Scholar 

  • Hall WA, Truwit CL (2008) Intraoperative MR-guided neurosurgery. J Magn Reson Imaging 27:368–375

    PubMed  Google Scholar 

  • Hall WA, Djalilian HR, Sperduto PW et al (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13:1642–1648

    CAS  PubMed  Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    CAS  PubMed  Google Scholar 

  • Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199

    CAS  PubMed  Google Scholar 

  • Hentschel SJ, Lang FF (2003) Current surgical management of glioblastoma. Cancer J 9:113–125

    PubMed  Google Scholar 

  • Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911

    CAS  PubMed  Google Scholar 

  • Hu X, Pandolfi PP, Li Y et al (2005) mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7: 356–368

    CAS  PubMed  Google Scholar 

  • Huncharek M (1998) Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 18:1935–1939

    CAS  PubMed  Google Scholar 

  • Jaeckle KA, Hess KR, Yung WK et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21:2305–2311

    CAS  PubMed  Google Scholar 

  • Jahnke K, Muldoon LL, Varallyay CG et al (2009) Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro-Oncology 11(2):142-50

    PubMed  Google Scholar 

  • Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622

    CAS  PubMed  Google Scholar 

  • Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535

    CAS  PubMed  Google Scholar 

  • Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379

    CAS  PubMed  Google Scholar 

  • Keles GE, Lamborn KR, Chang SM et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100:41–46

    PubMed  Google Scholar 

  • Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039–2049

    CAS  PubMed  Google Scholar 

  • Kleinberg L, Grossman SA, Carson K et al (2002) Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 20:3149–3155

    CAS  PubMed  Google Scholar 

  • Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108:467–470

    CAS  PubMed  Google Scholar 

  • Kreth FW, Warnke PC, Scheremet R et al (1993) Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 78:762–766

    CAS  PubMed  Google Scholar 

  • Kubsad SS, Mackie TR, Gehring MA et al (1990) Monte Carlo and convolution dosimetry for stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 19:1027–1035

    CAS  PubMed  Google Scholar 

  • Kunwar S, Chang SM, Prados MD et al (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20:E15

    PubMed  Google Scholar 

  • Kunwar S, Prados MD, Chang SM et al (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844

    CAS  PubMed  Google Scholar 

  • Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198

    CAS  PubMed  Google Scholar 

  • Lai A, Filka E, McGibbon B et al (2008a) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380

    CAS  PubMed  Google Scholar 

  • Lai A, Filka E, McGibbon B et al (2008b) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380

    CAS  PubMed  Google Scholar 

  • Laperriere NJ, Leung PM, McKenzie S et al (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:1005–1011

    CAS  PubMed  Google Scholar 

  • Lassman AB, DeAngelis LM (2003) Brain metastases. Neurol Clin 21:1–23

    PubMed  Google Scholar 

  • Lawson HC, Sampath P, Bohan E et al (2007) Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol 83:61–70

    CAS  PubMed  Google Scholar 

  • Leksell L (1951) The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102:316–319

    CAS  PubMed  Google Scholar 

  • Liang BC, Thornton AF Jr, Sandler HM et al (1991) Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559–563

    CAS  PubMed  Google Scholar 

  • Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8:343–359

    CAS  PubMed  Google Scholar 

  • Litofsky NS, Bauer AM, Kasper RS et al (2006) Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus 20:E16

    PubMed  Google Scholar 

  • Luptrawan A, Liu G, Yu JS (2008) Dendritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials 3:10–21

    PubMed  Google Scholar 

  • MacDonald SM, Ahmad S, Kachris S et al (2007) Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys 8:47–60

    PubMed  Google Scholar 

  • Maher EA, Furnari FB, Bachoo RM et al (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311–1333

    CAS  PubMed  Google Scholar 

  • Mandl ES, Dirven CM, Buis DR et al (2008) Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69:506–509; discussion 509

    PubMed  Google Scholar 

  • Medical-Research-Council-Brain-Tumour-Working-Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a trial of the Medical Research Council. J Clin Oncol 19:509–518

    Google Scholar 

  • Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    CAS  PubMed  Google Scholar 

  • Meyer FB, Bates LM, Goerss SJ et al (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687

    CAS  PubMed  Google Scholar 

  • Millauer B, Shawver LK, Plate KH et al (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579

    CAS  PubMed  Google Scholar 

  • Muacevic A, Kreth FW (2003) Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol 250:561–568

    PubMed  Google Scholar 

  • Narayana A, Yamada J, Berry S et al (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892–897

    PubMed  Google Scholar 

  • Nelson DF, Diener-West M, Horton J et al (1988) Combined modality approach to treatment of malignant gliomas – re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr: 279–284

    Google Scholar 

  • Nimsky C, Ganslandt O, Von Keller B et al (2004) Intraoperative high-field-strength MR imaging: implementation and experience in 200 patients. Radiology 233:67–78

    PubMed  Google Scholar 

  • Nimsky C, Ganslandt O, Buchfelder M et al (2006) Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res 28:482–487

    PubMed  Google Scholar 

  • Norden AD, Drappatz J, Ciampa AS et al (2009) Colon perforation during anti-angiogenic therapy for malignant glioma. Neuro-Oncology 11(1):92–95

    Google Scholar 

  • Norden AD, Young GS, Setayesh K et al (2008b) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    CAS  PubMed  Google Scholar 

  • Nwokedi EC, DiBiase SJ, Jabbour S et al (2002) Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50:41–46; discussion 46–47

    PubMed  Google Scholar 

  • Onoyama Y, Abe M, Yabumoto E et al 126:481–492

    CAS  PubMed  Google Scholar 

  • Perry J, Mason WP, Belanger K et al (2008) The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. J Clin Oncol 26: abstr 2010

    Google Scholar 

  • Pichlmeier U, Bink A, Schackert G et al (2008) Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neuro-Oncology 10(6):1025–1034

    PubMed  Google Scholar 

  • Plate K, Breier G, Weich H et al (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848

    CAS  PubMed  Google Scholar 

  • Pope WB, Lai A, Nghiemphu P et al (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260

    CAS  PubMed  Google Scholar 

  • Prados MD, Seiferheld W, Sandler HM, et al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147–1152

    CAS  PubMed  Google Scholar 

  • Prados MD, Lamborn KR, Chang S et al (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncology 8:67–78

    CAS  PubMed  Google Scholar 

  • Quant E, Norden A, Drappatz J et al (2008) Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J Clin Oncol 26, May 20 suppl; abstr 2008

    Google Scholar 

  • Quigley MR, Maroon JC (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29:385–388; discussion 388–389

    CAS  PubMed  Google Scholar 

  • Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev:CD007104

    Google Scholar 

  • Ramsey RG, Brand WN (1973) Radiotherapy of glioblastoma multiforme. J Neurosurg 39:197–202

    CAS  PubMed  Google Scholar 

  • Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397

    CAS  PubMed  Google Scholar 

  • Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122

    CAS  PubMed  Google Scholar 

  • Reardon DA, Nabors LB, Stupp R et al (2008a) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17:1225–1235

    CAS  PubMed  Google Scholar 

  • Reardon DA, Zalutsky MR, Akabani G et al (2008b) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology 10:182–189

    CAS  PubMed  Google Scholar 

  • Regina A, Demeule M, Che C et al (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155:185–197

    CAS  PubMed  Google Scholar 

  • Rich J, Reardon D, Peery T et al (2004a) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    CAS  PubMed  Google Scholar 

  • Rich JN, Reardon DA, Peery T et al (2004b) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    CAS  PubMed  Google Scholar 

  • Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588

    CAS  PubMed  Google Scholar 

  • Salazar OM, Rubin P, Feldstein ML et al (1979) High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 5:1733–1740

    CAS  PubMed  Google Scholar 

  • Sampson JH, Akabani G, Archer GE et al (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology 10:320–329

    CAS  PubMed  Google Scholar 

  • Schryver AD, Greitz T, Forsby N et al (1976) Localized shaped field radiotherapy of malignant glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1:713–716

    CAS  PubMed  Google Scholar 

  • Schulz-Ertner D, Tsujii H (2007) Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 25:953–964

    PubMed  Google Scholar 

  • Selker RG, Shapiro WR, Burger P et al (2002) The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343–355; discussion 355–347

    PubMed  Google Scholar 

  • Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239–244

    CAS  PubMed  Google Scholar 

  • Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    CAS  PubMed  Google Scholar 

  • Sneed PK, Lamborn KR, Larson DA et al (1996) Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37–44

    CAS  PubMed  Google Scholar 

  • Soffietti R, Ruda R, Bradac GB et al (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066–1073

    CAS  PubMed  Google Scholar 

  • Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int J Radiat Oncol Biol Phys 60:853–860

    PubMed  Google Scholar 

  • Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncology 7:369

    Google Scholar 

  • Stefanik DF, Rizkalla LR, Soi A et al (1991) Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51:5760–5765

    CAS  PubMed  Google Scholar 

  • Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    CAS  PubMed  Google Scholar 

  • Stieber VW, Ellis TL (2005) The role of radiosurgery in the management of malignant brain tumors. Curr Treat Options Oncol 6:501–508

    PubMed  Google Scholar 

  • Stieber VW, Mehta MP (2007) Advances in radiation therapy for brain tumors. Neurol Clin 25:1005–1033, ix

    PubMed  Google Scholar 

  • Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287–290

    CAS  PubMed  Google Scholar 

  • Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401

    CAS  PubMed  Google Scholar 

  • Stummer W, Reulen HJ, Meinel T et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564–576

    PubMed  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    CAS  PubMed  Google Scholar 

  • Stupp R, Hegi ME, Gilbert MR et al (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136

    CAS  PubMed  Google Scholar 

  • Tatter SB, Shaw EG, Rosenblum ML et al (2003) An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 99:297–303

    PubMed  Google Scholar 

  • Thornton AF, Jr., Hegarty TJ, Ten Haken RK et al (1991) Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 20:1309–1315

    PubMed  Google Scholar 

  • Thornton AF Jr, Sandler HM, Ten Haken RK et al (1992) The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys 24:767–775

    PubMed  Google Scholar 

  • Tsao MN, Mehta MP, Whelan TJ et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 63:47–55

    PubMed  Google Scholar 

  • Unsgaard G, Rygh OM, Selbekk T et al (2006) Intra-operative 3D ultrasound in neurosurgery. Acta Neurochir (Wien) 148:235–253; discussion 253

    CAS  Google Scholar 

  • Valk PE, Dillon WP (1991) Radiation injury of the brain. AJNR Am J Neuroradiol 12:45–62

    CAS  PubMed  Google Scholar 

  • van den Bent MJ (2007) Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 25:1089–1109

    PubMed  Google Scholar 

  • van den Bent MJ, Kros JM, Heimans JJ et al (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145

    PubMed  Google Scholar 

  • van den Bent MJ, Chinot O, Boogerd W et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599–602

    PubMed  Google Scholar 

  • van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    PubMed  Google Scholar 

  • Vogelbaum MA (2007) Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol 83:97–109

    PubMed  Google Scholar 

  • Vogelbaum MA, Berkey B, Peereboom D et al (2009) Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology 11(2):167–175

    PubMed  Google Scholar 

  • Vredenburgh JJ, Desjardins A, Herndon JE et al (2006) Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas J Clin Oncol 24: abstr. 1506

    Google Scholar 

  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007a) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259

    CAS  PubMed  Google Scholar 

  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007b) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    CAS  PubMed  Google Scholar 

  • Wagner GL, Wilms EB, Van Donselaar CA et al (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586

    CAS  PubMed  Google Scholar 

  • Walker MD, Alexander E Jr, Hunt WE et al (1976) Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44:655–667

    CAS  PubMed  Google Scholar 

  • Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343

    CAS  PubMed  Google Scholar 

  • Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731

    CAS  PubMed  Google Scholar 

  • Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329

    CAS  PubMed  Google Scholar 

  • Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3–13

    PubMed  Google Scholar 

  • Weber F, Asher A, Bucholz R et al (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125–137

    PubMed  Google Scholar 

  • Welsh J, Sanan A, Gabayan AJ et al (2007) GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68:159–165

    PubMed  Google Scholar 

  • Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res 12:4899–4907

    CAS  PubMed  Google Scholar 

  • Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88

    CAS  PubMed  Google Scholar 

  • Westphal M, Ram Z, Riddle V et al (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269–275; discussion 275

    CAS  Google Scholar 

  • Whittle IR, Pringle AM, Taylor R (1998) Effects of resective surgery for left-sided intracranial tumours on language function: a prospective study. Lancet 351:1014–1018

    CAS  PubMed  Google Scholar 

  • Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115

    CAS  PubMed  Google Scholar 

  • Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361

    CAS  PubMed  Google Scholar 

  • Willett CG, Boucher Y, Duda DG et al (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136–8139

    PubMed  Google Scholar 

  • Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578

    CAS  PubMed  Google Scholar 

  • Wood JR, Green SB, Shapiro WR (1988) The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338–343

    CAS  PubMed  Google Scholar 

  • Yamanaka R (2008) Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14:228–235

    CAS  PubMed  Google Scholar 

  • Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    CAS  PubMed  Google Scholar 

  • Zaremba T, Curtin NJ (2007) PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 7:515–523

    CAS  PubMed  Google Scholar 

  • Zuniga RM, Torcuator R, Doyle T et al (2008) Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. J Clin Oncol 26(May suppl.): abstr. 13013

    Google Scholar 

Download references

Acknowledgement

We gratefully acknowledge the generous support of the William F. Borhek Fund for Brain Tumor Research.

Author information

Authors and Affiliations

  1. Department of Neurology, Brigham and Women’s Hospital and Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, 44 Binney Street, Boston, MA, 02115, USA

    Jan Drappatz

Authors
  1. Jan Drappatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew D. Norden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Y. Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Drappatz .

Editor information

Editors and Affiliations

  1. Inst. Chemie und Biochemie, FU Berlin, Thielallee 63, Berlin, 14195, Germany

    Volker A. Erdmann

  2. Inst. Neuropathologie, Universitätsklinikum Düsseldorf, Moorenstr. 5, Düsseldorf, 40225, Germany

    Guido Reifenberger

  3. Inst. Bioorganic Chemistry, PAN Poznan, ul. Z. Noskowskiego 12/14, Poznan, 61-704, Poland

    Jan Barciszewski

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Drappatz, J., Norden, A.D., Wen, P.Y. (2009). Treatment of High-Grade Gliomas in Adults. In: Erdmann, V., Reifenberger, G., Barciszewski, J. (eds) Therapeutic Ribonucleic Acids in Brain Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00475-9_16

Download citation

Publish with us

Policies and ethics

Search

Navigation